Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Side effects of ado-trastuzumab emtansine impacting outcomes in patients with HER2+ advanced breast cancer

Posted by on Aug 25, 2019 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate the impact of early side effects requiring ado-trastuzumab emtansine dose interruptions or reductions on outcomes for patients with HER2+ advanced metastatic breast cancer.  This study concluded that these side effects do not impact the outcomes for these patients.   Some background...

Read More

Searching for patients with advanced triple-negative breast cancer to test a new combination treatment

Posted by on Aug 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...

Read More

Searching for patients with advanced non-small cell lung cancer to test a new combination therapy

Posted by on Aug 22, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...

Read More

How effective is alpelisib in hormone-receptor positive breast cancer with PIK3CA-mutations?

Posted by on Aug 14, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness of alpelisib (Piqray) in hormone receptor-positive (HR+) -human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC). They found that alpelisib significantly improved survival in patients with PIK3CA mutations.  Some background Breast cancer (BC) types can be...

Read More

Looking for participants with advanced colorectal cancer to test a new immunotherapy

Posted by on Aug 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...

Read More

Looking for participants with metastatic non-small cell lung cancer to test a new immunotherapy

Posted by on Aug 14, 2019 in Lung cancer | 0 comments

In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...

Read More

Looking for participants with metastatic melanoma to test a new immunotherapy

Posted by on Aug 14, 2019 in Melanoma | 0 comments

In a nutshell This phase 1 trial is examining the effectiveness of personalized tumor antigens (PTA) in the treatment of different advanced tumors. The main outcomes to be measured will be side effects and disease control. This study is being conducted in Arizona, California, Louisiana and New Jersey, US. The details While the tumor cells are growing,...

Read More

Looking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination

Posted by on Aug 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...

Read More

Searching patients with triple-negative breast cancer to trial a new treatment combination

Posted by on Jul 29, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...

Read More

Searching for patients to try a new therapy for advanced solid tumors.

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...

Read More

Looking for participants with advanced colorectal cancer to test a new combined treatment

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the effectiveness of liposomal irinotecan (LI; Onivyde) and rucaparib (Rubraca) in treating patients with advanced colorectal cancer. The main outcome to be measured will be the toxicity and tumor response to the treatment. This trial is being conducted in Arizona, Georgia, Minnesota, and Utah, US. The...

Read More